Reducing inappropriate testing in the diagnosis of the menopause and peri-menopause.

Post Reprod Health

Blood Sciences Department, Dumfries and Galloway Royal Infirmary, Dumfries, UK.

Published: September 2016


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The menopause should be diagnosed based on age, menstrual history and clinical symptoms, and as such, follicle stimulating hormone testing may be considered inappropriate when diagnosing the menopause or peri-menopause in women aged 45 and over. As part of a demand optimisation programme, the number of follicle stimulating hormone tests requested to diagnose the menopause in this age group was quantified and educational interventions were implemented to reduce inappropriate testing. The number of follicle stimulating hormone tests requested to diagnose the menopause in women aged 45 and over was successfully and sustainably reduced.

Download full-text PDF

Source
http://dx.doi.org/10.1177/2053369116634960DOI Listing

Publication Analysis

Top Keywords

follicle stimulating
12
stimulating hormone
12
inappropriate testing
8
menopause peri-menopause
8
women aged
8
number follicle
8
hormone tests
8
tests requested
8
requested diagnose
8
diagnose menopause
8

Similar Publications

Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.

Methods: This was a hospital data-based retrospective study.

View Article and Find Full Text PDF

In recent years, the potential application of Hook f. (TWHF) in the treatment of rheumatoid arthritis (RA) has garnered increasing attention in both academic research and clinical practice. However, the effective use of is limited in clinical practice by its severe toxic side effects.

View Article and Find Full Text PDF

Introduction: Several studies indicate that a specific genotype profile could influence ovarian sensitivity to exogenous gonadotropin. However, most of the previous studies were observational and retrospective and thereby more prone to bias. The aim of this study was to evaluate the impact of gonadotropin single nucleotide polymorphisms (SNPs) on the outcomes of fertilization (IVF) in infertile patients undergoing their first ovarian stimulation (OS) cycle.

View Article and Find Full Text PDF

Hypergonadotropic hypogonadism is usually caused by the impairment of the structure and function of the gonads, but there are cases caused by reduced stimulation by the follicle-stimulating hormone (FSH) as a result of abnormal variants of genes encoding the follicle-stimulating hormone or its receptor (FSHR). We present the case of an elite athlete with the c.2039A>G variant in one allele of the FSHR gene resulting in hypergonadotropic hypogonadism, low testicular volume, and reduced semen parameters, placing particular emphasis on the diagnostic process and the importance of correct diagnosis in the context of possible treatment with gonadotropins, which can significantly improve fertility, increase testosterone levels, and, in the case of athletes, obtain approval from the anti-doping organization for treatment that increases testosterone levels.

View Article and Find Full Text PDF

Imidacloprid (IMI) is an insect-selective synthetic nicotine derivative used in commercial agricultural systems, home gardening, and veterinary pharmaceuticals. People are exposed to IMI through consumption of contaminated food and water and through contact with companion animals. However, the effects of IMI on the female reproductive system are not well understood.

View Article and Find Full Text PDF